SERUM S100-B AS A TOOL TO PREDICT COMPUTED CRANIAL TOMOGRAPHY FINDINGS IN MILD BRAIN INJURY

D. Zongo*, R. Ribereau-Gayon, F. Masson, E. Lagarde Correspondence: PPCT (Prévention et prise en charge des traumatismes) ISPED-Bordeaux, INSERM U897 - Case 11 Université Victor Segalen Bordeaux 2 146 rue Leo Saignat 33076 BORDEAUX 33076, France

Background Minor head injury (MHI) has a high incidence and implies a risk of brain injury. Cranial computed tomography (CCT) is recommended for early detection of these lesions. However, the indication of CCT is based on non-specific clinical symptoms. Protein S100-B was then suggested as a promising tool to identify those patients with no risk of cranial injury.

Objective To evaluate S100-B as a screening tool in the management of MHI.

Methods Patients attending Bordeaux emergency department with an isolated MHI were consecutively included during 15 months. Blood samples were drawn within 6 h after head injury to assess S100-B level.

Results 1559 patients were included. CCT was indicative of cranial injury in 112 patients (7%). At the threshold of 0.10 g/l, S100B has a sensitivity of 99% (95% CI 95 to 100),
a specificity of 12% (11–14) and a negative predictive value (NPV) of 99% (97–100) as compared with CCT results. 12% of the patients has a S100-B level below this threshold and therefore could have been discharged with CCT. A threshold of 0.12 μg/L proved however to be the best compromise between sensitivity (99%), specificity (20%) and a NPV of 99.7% (98–100) with CCT potentially avoided for 19% of the patients.

**Discussion** Early determination of S100-B blood levels is highly sensitive to detect CCT abnormalities. The threshold of 0.12 μg/L was the best compromise between sensitivity and specificity in our study.